Centre for Commercialization of Cancer Immunotherapy (C3i)
The Centre for Commercialization of Cancer Immunotherapy (C3i) will accelerate discovery, commercialization and access to innovative cancer immunotherapies for patients..
Operating out of the Hôpital Maisonneuve-Rosemont installation of the Integrated University Center of East Montreal (CIUSS de l’Est-de-l’île-de-Montréal), the centre will offer an integrated structure for the development, translation and commercialization of these groundbreaking therapies. C3i will combine three interacting units that will provide patients with cutting edge biomarker and diagnostic tests, good manufacturing practices standards and rapid access to clinical trials and regulatory support to bring effective and affordable remedies more rapidly to Canadians and the world. This will strengthen Canada’s position as a leader in the emerging field of cancer immunotherapy.
Immunotherapy is a rapidly emerging practice that harnesses the power of the immune system to combat cancer. It could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents, thus improving patients’ quality of life and reducing healthcare costs. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help Canadian companies compete in a potential $40 billion market.
Contact Information
François Bettez B.Sc. M.Sc.
CEO
francois.bettez.cemtl@ssss.gouv.qc.ca
Louisa Petropoulos
Business Developer
louisa.petropoulos.cemtl@ssss.gouv.qc.ca